Monitor upcoming investor presentations at the Swiss Biotech Conference for further details on development timelines or preclinical data. Absence of financial terms suggests this is a research-level collaboration, limiting near-term commercial impact.
Price Chart
Executive Summary
NewcelX announced an updated corporate presentation highlighting its strategic collaboration with Eledon Pharmaceuticals to combine stem-cell-derived islet therapy NCEL-101 with Eledon's immune-modulating drug tegoprubart for Type 1 Diabetes. The partnership aims to improve graft survival and advance toward a functional cure, with management set to present the strategy at the upcoming Swiss Biotech Conference.
Key Facts
- NewcelX released an updated corporate presentation featuring its collaboration with Eledon Pharmaceuticals (Nasdaq: ELDN).
- The collaboration combines NCEL-101 (stem-cell-derived islet replacement) with tegoprubart (anti-CD40L mAb) to prevent transplant rejection.
- Focus is on advancing a potential functional cure for Type 1 Diabetes through combined cell therapy and immune modulation.
- Management plans to present the updated strategy at the Swiss Biotech Conference.
Financial Impact
No financial terms disclosed; collaboration does not include upfront payment or equity exchange.
Risk Factors
- Preclinical stage risk: No guarantee that lab results will translate to clinical success.
- Dependence on unproven combination therapy increasing development complexity.
- No funding or milestone commitments disclosed, suggesting limited near-term value creation.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3276901 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 23, 2026 4w ago | EFFECT | $2.86 $3.08 | ▼ −7.52% | ▼ −8.19% | $2.55 (+10.84%) |
Sep 18, 2026 5w ago | 6-K | $2.97 $2.92 | ▲ +1.68% | ▲ +0.66% | $2.55 (+14.14%) |
Aug 27, 2026 8w ago | EFFECT | $3.42 $3.35 | ▲ +2.05% | ▲ +1.28% | $2.55 (+25.44%) |
Jul 31, 2026 12w ago | 6-K | $3.49 $3.31 | ▼ −5.16% | ▼ −8.67% | $2.55 (−26.93%) |
Jul 15, 2026 14w ago | 6-K | $3.93 $3.65 | ▼ −7.12% | ▼ −6.14% | $2.55 (−35.11%) |
Jul 8, 2026 15w ago | 6-K | $4.23 $3.98 | ▼ −5.91% | ▼ −6.77% | $2.55 (−39.72%) |
Jul 1, 2026 16w ago | 6-K | $3.85 $4.01 | ▲ +4.16% | ▲ +3.89% | $2.55 (−33.77%) |
Jun 30, 2026 16w ago | 6-K | $3.85 $4.01 | ▲ +4.16% | ▲ +3.89% | $2.55 (−33.77%) |
Jun 18, 2026 18w ago | EFFECT | $3.31 $3.55 | ▼ −7.25% | ▼ −8.92% | $2.55 (+22.96%) |
Jun 5, 2026 20w ago | 6-K | $3.24 $3.20 | ▼ −1.23% | ▼ −3.35% | $2.55 (−21.30%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers